Preventing cytomegalovirus (CMV) infections in patients receiving bone marrow transplants

Genovefa Papanicolaou, MD, from the Memorial Sloan Kettering Cancer Center, New York City, NY, discusses new therapies for the treatment or prevention of viral infections in patients receiving bone marrow transplants at the American Society of Hematology (ASH) Congress 2016 in San Diego, CA. Over the last 10 to 15 years, Dr Papanicolaou has been involved in trials trying to prevent cytomegalovirus (CMV), which is a major problem in patients receiving bone marrow transplants. She discusses the exciting results of a CMV-prevention trial with letermovir, which has met its primary endpoint (NCT02137772). For patients who receive allogeneic stem cell transplants, this is great news, as CMV infection has large impacts on both their quality of life and morbidity

Share this video